CN113768021A - 一种具有降血脂、降血糖作用的压片果糖及其制备方法 - Google Patents
一种具有降血脂、降血糖作用的压片果糖及其制备方法 Download PDFInfo
- Publication number
- CN113768021A CN113768021A CN202111273487.7A CN202111273487A CN113768021A CN 113768021 A CN113768021 A CN 113768021A CN 202111273487 A CN202111273487 A CN 202111273487A CN 113768021 A CN113768021 A CN 113768021A
- Authority
- CN
- China
- Prior art keywords
- parts
- fructose
- polysaccharide
- rosa roxburghii
- blood sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 80
- 210000004369 blood Anatomy 0.000 title claims abstract description 79
- 229930091371 Fructose Natural products 0.000 title claims abstract description 33
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 title claims abstract description 33
- 239000005715 Fructose Substances 0.000 title claims abstract description 33
- 230000001603 reducing effect Effects 0.000 title claims abstract description 31
- 150000002632 lipids Chemical class 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title abstract description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 38
- 150000004676 glycans Chemical class 0.000 claims abstract description 38
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 38
- 239000005017 polysaccharide Substances 0.000 claims abstract description 38
- 240000002547 Rosa roxburghii Species 0.000 claims abstract description 31
- 235000000640 Rosa roxburghii Nutrition 0.000 claims abstract description 31
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 20
- 229910052742 iron Inorganic materials 0.000 claims abstract description 19
- 239000008518 lycium barbarum polysaccharide Substances 0.000 claims abstract description 19
- 239000000945 filler Substances 0.000 claims abstract description 16
- 239000000314 lubricant Substances 0.000 claims abstract description 16
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims description 16
- 239000002994 raw material Substances 0.000 claims description 14
- 229920002472 Starch Polymers 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 239000008107 starch Substances 0.000 claims description 13
- 235000019698 starch Nutrition 0.000 claims description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 238000007873 sieving Methods 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 7
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 235000012239 silicon dioxide Nutrition 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 3
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229960001855 mannitol Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 238000007908 dry granulation Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 229940032147 starch Drugs 0.000 claims description 2
- 238000005550 wet granulation Methods 0.000 claims description 2
- 235000013305 food Nutrition 0.000 abstract description 2
- 230000036541 health Effects 0.000 abstract description 2
- 241000220317 Rosa Species 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003345 hyperglycaemic effect Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 244000182216 Mimusops elengi Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000005523 excessive nutrition Nutrition 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000002727 hyperosmolar Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/362—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及食品保健领域,公开了一种具有降血脂、降血糖作用的压片果糖及其制备方法,按重量份数计,包括如下组分:15‑30份刺梨多糖、5‑10份刺梨多糖铁、10‑20份壳寡糖、1‑5份枸杞多糖、10‑45份填充剂、0.1‑8份崩解剂、0.1‑5份润滑剂,本发明制备的压片果糖具有降血脂、降血糖的作用。
Description
技术领域
本发明涉及食品保健领域,特别是一种具有降血脂、降血糖作用的压片果糖及其制备方法。
背景技术
糖尿病是一种由于胰岛素分泌缺陷或胰岛素作用障碍所致的以高血糖为特征的代谢性疾病。持续高血糖与长期代谢紊乱等可导致全身组织器官,特别是眼、肾、心血管及神经系统的损害及其功能障碍和衰竭。严重者可引起失水,电解质紊乱和酸碱平衡失调等急性并发症酮症酸中毒和高渗昏迷。
随着人们生活水平的提高,物质生活的丰富,从而导致人们摄取较多的营养物质,导致营养过剩从而引发糖尿病、高血压、高血糖等多发病症,此类病症需要患者从饮食、运动、药物等多方面进行着手治疗,现有的治疗药物降血糖效果较为有限,且营养元素较少,营养价值不高。
发明内容
为此,需要提供一种具有降血脂、降血糖作用的压片果糖及其制备方法,解决现有的治疗药物降血糖效果较为有限,且营养元素较少,营养价值不高的问题。
为实现上述目的,本发明提供了一种具有降血脂、降血糖作用的压片果糖,按重量份数计,包括如下组分:15-30份刺梨多糖、5-10份刺梨多糖铁、 10-20份壳寡糖、1-5份枸杞多糖、10-45份填充剂、0.1-8份崩解剂、0.1-5 份润滑剂。
进一步,所述刺梨多糖和刺梨多糖铁的重量比为4-3:1。
进一步,所述刺梨多糖铁中铁的含量控制为20-30%。
进一步,所述填充剂为淀粉、可压性淀粉、微晶纤维素、乳糖、糊精、低聚果糖、甘露醇、木糖醇、山梨醇中的一种或几种;所述崩解剂为羧甲基淀粉钠、低取代羟丙基纤维素、交联羧甲基纤维素钠中的一种或几种;所述润滑剂为硬脂酸镁、二氧化硅、微粉硅胶中的一种或几种。
进一步,按重量份数计,包括如下组分:20份刺梨多糖、5份刺梨多糖铁、15份壳寡糖、3份枸杞多糖、30份填充剂、0.5份崩解剂、2份润滑剂。
进一步,按重量份数计,包括如下组分:30份刺梨多糖、10份刺梨多糖铁、10份壳寡糖、1份枸杞多糖、45份填充剂、5份崩解剂、3份润滑剂。
上述的具有降血脂、降血糖作用的压片果糖的制备方法,包括如下步骤:
(1)按配方比例称取刺梨多糖、刺梨多糖铁、壳寡糖、枸杞多糖、填充剂、崩解剂、润滑剂,混合过筛得到混合原料;
(2)将混合原料压片得到具有降血脂、降血糖作用的压片果糖。
进一步,所述过筛粒径为100-200目。
进一步,压片方法包括湿法制粒压片、干法制粒压片或直接压片。
上述技术方案具有以下有益效果:
本发明中组分中刺梨多糖、刺梨多糖铁、壳寡糖和枸杞多糖能够相互协同,起到降血糖、降血脂的作用,同时刺梨多糖铁也能够在一定程度上作为补铁剂及时为机体补充铁元素。
具体实施方式
为详细说明技术方案的技术内容、构造特征、所实现目的及效果,以下结合具体实施例详予说明。
实施例1
一种具有降血脂、降血糖作用的压片果糖,按重量份数计,包括如下组分:20份刺梨多糖、5份刺梨多糖铁、15份壳寡糖、3份枸杞多糖、20份淀粉、10份山梨醇、0.5份羧甲基淀粉钠、2份硬脂酸镁。
制备过程包括:
(1)按配方比例称取刺梨多糖、刺梨多糖铁、壳寡糖、枸杞多糖、填充剂、崩解剂、润滑剂,混合过100目筛得到混合原料;
(2)将混合原料通过直接压片得到具有降血脂、降血糖作用的压片果糖。
实施例2
一种具有降血脂、降血糖作用的压片果糖,按重量份数计,包括如下组分:30份刺梨多糖、10份刺梨多糖铁、10份壳寡糖、1份枸杞多糖、20份可压性淀粉、15份微晶纤维素、10份低聚果糖、5份低取代羟丙基纤维素、3 份二氧化硅。
制备过程包括:
(1)按配方比例称取刺梨多糖、刺梨多糖铁、壳寡糖、枸杞多糖、填充剂、崩解剂、润滑剂,混合过200目筛得到混合原料;
(2)将混合原料通过湿法制粒压片得到具有降血脂、降血糖作用的压片果糖。
实施例3
一种具有降血脂、降血糖作用的压片果糖,按重量份数计,包括如下组分:15份刺梨多糖、10份刺梨多糖铁、20份壳寡糖、5份枸杞多糖、10份淀粉、15份乳糖、10份糊精、2份交联羧甲基纤维素钠、1份微粉硅胶。
制备过程包括:
(1)按配方比例称取刺梨多糖、刺梨多糖铁、壳寡糖、枸杞多糖、填充剂、崩解剂、润滑剂,混合过100目筛得到混合原料;
(2)将混合原料通过干法制粒压片得到具有降血脂、降血糖作用的压片果糖。
实施例4
一种具有降血脂、降血糖作用的压片果糖,按重量份数计,包括如下组分:15份刺梨多糖、5份刺梨多糖铁、10份壳寡糖、1份枸杞多糖、10份淀粉、0.1份低取代羟丙基纤维素、0.1份二氧化硅。
制备过程包括:
(1)按配方比例称取刺梨多糖、刺梨多糖铁、壳寡糖、枸杞多糖、填充剂、崩解剂、润滑剂,混合过200目筛得到混合原料;
(2)将混合原料通过湿法制粒压片得到具有降血脂、降血糖作用的压片果糖。
实施例5
一种具有降血脂、降血糖作用的压片果糖,按重量份数计,包括如下组分:30份刺梨多糖、10份刺梨多糖铁、10份壳寡糖、5份枸杞多糖、20份可压性淀粉、5份甘露醇、5份木糖醇、1份羧甲基淀粉钠、1份硬脂酸镁。
制备过程包括:
(1)按配方比例称取刺梨多糖、刺梨多糖铁、壳寡糖、枸杞多糖、填充剂、崩解剂、润滑剂,混合过200目筛得到混合原料;
(2)将混合原料通过湿法制粒压片得到具有降血脂、降血糖作用的压片果糖。
实施例1-5制备的压片果糖进行动物降血糖和降血脂实验。
1.降血糖实验
1.1实验动物:SPF级昆明种雄性小鼠,体重为18-22g。
1.2实验环境:实验期间环境温度为22-24℃,湿度52-58%。
1.3高血糖模型动物:小鼠禁食24小时后,尾静脉注射四氧嘧啶 (46mg/kg.bw),5天后禁食5小时,测血糖值,血糖值在10-25mmol/L之间为高血糖模型成功动物,选高血糖模型成功小鼠60只,随机分成一个模型组和五个测试组(组间血糖差不大于1.1mmol/L)。以10只正常小鼠作为空白组。
五个测试组分别灌胃实施例1-5的压片糖果,灌胃量0.15g/kg,模型组灌胃等量的生理盐水,空白组灌胃等量生理盐水,每天一次,连续30天禁食 5小时测空腹血糖值,比较各组动物血糖值及血糖下降百分比。
1.5实验结果
血糖下降百分率=(实验前血糖值-实验后血糖值)/实验前血糖值×100 %。
实验结果如下表1
表1压片果糖的血糖实验结果
2.降血脂实验
2.1实验动物:SPF级雄性KM小鼠,体重为18-22g。
2.2高脂小鼠:小鼠饲养高脂饲料(78.8%基础饲料,1%胆固醇,10%猪油, 10%蛋黄粉,0.2%胆酸盐),正常光照,每周称重一次,饲养28天,造模成功。
选高脂模型成功小鼠70只,随机分成7组,每组10只,1组模型组,1 组阳性对照组,5个测试组。以正常10只小鼠为空白组。
五个测试组分别灌胃实施例1-5的压片糖果,灌胃量0.15g/kg,空白组和模型组灌胃等量的生理盐水,阳性对照组灌胃辛伐他汀溶液4mg/kg。
每天一次,连续30天。
2.3实验处理
小鼠血清:灌胃30天后,将小鼠禁食不禁水,12h,眼球取血,收集到血清管中,放置2h后离心处理,将血清分离置于离心管中。
2.4指标测量
使用总胆固醇(TC)、总甘油三酯(TG)和高密度脂蛋白(HDL-C)测定试剂盒对小鼠血清指标进行测定。
2.5测定结果
实验结果如表2所示
表2.压片果糖的降血脂实验
由以上两组实验可知,本发明制备的压片果糖具有良好的降血糖和降血脂的功效,且压片组分的相互作用能够使得降血糖和降血脂相对于现有药物有进一步的提高。
需要说明的是,在本文中,诸如第一和第二等之类的关系术语仅仅用来将一个实体或者操作与另一个实体或操作区分开来,而不一定要求或者暗示这些实体或操作之间存在任何这种实际的关系或者顺序。而且,术语“包括”、“包含”或者其任何其他变体意在涵盖非排他性的包含,从而使得包括一系列要素的过程、方法、物品或者终端设备不仅包括那些要素,而且还包括没有明确列出的其他要素,或者是还包括为这种过程、方法、物品或者终端设备所固有的要素。在没有更多限制的情况下,由语句“包括……”或“包含……”限定的要素,并不排除在包括所述要素的过程、方法、物品或者终端设备中还存在另外的要素。此外,在本文中,“大于”、“小于”、“超过”等理解为不包括本数;“以上”、“以下”、“以内”等理解为包括本数。
尽管已经对上述各实施例进行了描述,但本领域内的技术人员一旦得知了基本创造性概念,则可对这些实施例做出另外的变更和修改,所以以上所述仅为本发明的实施例,并非因此限制本发明的专利保护范围,凡是利用本发明说明书内容所作的等效结构或等效流程变换,或直接或间接运用在其他相关的技术领域,均同理包括在本发明的专利保护范围之内。
Claims (9)
1.一种具有降血脂、降血糖作用的压片果糖,其特征在于,按重量份数计,包括如下组分:15-30份刺梨多糖、5-10份刺梨多糖铁、10-20份壳寡糖、1-5份枸杞多糖、10-45份填充剂、0.1-8份崩解剂、0.1-5份润滑剂。
2.如权利要求1所述的具有降血脂、降血糖作用的压片果糖,其特征在于,所述刺梨多糖和刺梨多糖铁的重量比为4-3:1。
3.如权利要求1所述的具有降血脂、降血糖作用的压片果糖,其特征在于,所述刺梨多糖铁中铁的含量控制为20-30%。
4.如权利要求1所述的具有降血脂、降血糖作用的压片果糖,其特征在于,所述填充剂为淀粉、可压性淀粉、微晶纤维素、乳糖、糊精、低聚果糖、甘露醇、木糖醇、山梨醇中的一种或几种;所述崩解剂为羧甲基淀粉钠、低取代羟丙基纤维素、交联羧甲基纤维素钠中的一种或几种;所述润滑剂为硬脂酸镁、二氧化硅、微粉硅胶中的一种或几种。
5.如权利要求1所述的具有降血脂、降血糖作用的压片果糖,其特征在于,按重量份数计,包括如下组分:20份刺梨多糖、5份刺梨多糖铁、15份壳寡糖、3份枸杞多糖、30份填充剂、0.5份崩解剂、2份润滑剂。
6.如权利要求1所述的具有降血脂、降血糖作用的压片果糖,其特征在于,按重量份数计,包括如下组分:30份刺梨多糖、10份刺梨多糖铁、10份壳寡糖、1份枸杞多糖、45份填充剂、5份崩解剂、3份润滑剂。
7.如权利要求1-6任一所述的具有降血脂、降血糖作用的压片果糖的制备方法,其特征在于,包括如下步骤:
(1)按配方比例称取刺梨多糖、刺梨多糖铁、壳寡糖、枸杞多糖、填充剂、崩解剂、润滑剂,混合过筛得到混合原料;
(2)将混合原料压片得到具有降血脂、降血糖作用的压片果糖。
8.如权利要求7所述的具有降血脂、降血糖作用的压片果糖的制备方法,其特征在于,所述过筛粒径为100-200目。
9.如权利要求7所述的具有降血脂、降血糖作用的压片果糖的制备方法,其特征在于,压片方法包括湿法制粒压片、干法制粒压片或直接压片。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111273487.7A CN113768021A (zh) | 2021-10-29 | 2021-10-29 | 一种具有降血脂、降血糖作用的压片果糖及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111273487.7A CN113768021A (zh) | 2021-10-29 | 2021-10-29 | 一种具有降血脂、降血糖作用的压片果糖及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113768021A true CN113768021A (zh) | 2021-12-10 |
Family
ID=78873584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111273487.7A Pending CN113768021A (zh) | 2021-10-29 | 2021-10-29 | 一种具有降血脂、降血糖作用的压片果糖及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113768021A (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101073370A (zh) * | 2007-06-22 | 2007-11-21 | 上海新康制药厂 | 一种刺梨糖果制品及其制备方法 |
CN105192225A (zh) * | 2015-08-26 | 2015-12-30 | 王佳英 | 一种刺梨软糖及其加工方法 |
CN105494844A (zh) * | 2014-10-20 | 2016-04-20 | 威海新异生物科技有限公司 | 一种枸杞压片糖果生产方法 |
CN108498540A (zh) * | 2018-05-24 | 2018-09-07 | 贵州黔之爱生物科技有限公司 | 一种刺梨多糖铁的制作方法 |
CN108935905A (zh) * | 2018-10-15 | 2018-12-07 | 贵州极海果蔬饮品工程技术有限公司 | 刺梨糖片制备方法 |
CN109400734A (zh) * | 2018-10-17 | 2019-03-01 | 华南理工大学 | 一种刺梨多糖及其制备方法与应用 |
CN109805147A (zh) * | 2019-02-25 | 2019-05-28 | 青海淼塔源农牧科技有限公司 | 一种红枸杞多糖咀嚼片及其制备工艺 |
CN110353073A (zh) * | 2019-08-27 | 2019-10-22 | 广东工业大学 | 一种降压硬糖及其制备方法 |
CN112219923A (zh) * | 2020-10-20 | 2021-01-15 | 贵州黔之爱生物科技有限公司 | 降血脂降血糖的刺梨食用菌茶叶发酵饮料的制备及应用 |
-
2021
- 2021-10-29 CN CN202111273487.7A patent/CN113768021A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101073370A (zh) * | 2007-06-22 | 2007-11-21 | 上海新康制药厂 | 一种刺梨糖果制品及其制备方法 |
CN105494844A (zh) * | 2014-10-20 | 2016-04-20 | 威海新异生物科技有限公司 | 一种枸杞压片糖果生产方法 |
CN105192225A (zh) * | 2015-08-26 | 2015-12-30 | 王佳英 | 一种刺梨软糖及其加工方法 |
CN108498540A (zh) * | 2018-05-24 | 2018-09-07 | 贵州黔之爱生物科技有限公司 | 一种刺梨多糖铁的制作方法 |
CN108935905A (zh) * | 2018-10-15 | 2018-12-07 | 贵州极海果蔬饮品工程技术有限公司 | 刺梨糖片制备方法 |
CN109400734A (zh) * | 2018-10-17 | 2019-03-01 | 华南理工大学 | 一种刺梨多糖及其制备方法与应用 |
CN109805147A (zh) * | 2019-02-25 | 2019-05-28 | 青海淼塔源农牧科技有限公司 | 一种红枸杞多糖咀嚼片及其制备工艺 |
CN110353073A (zh) * | 2019-08-27 | 2019-10-22 | 广东工业大学 | 一种降压硬糖及其制备方法 |
CN112219923A (zh) * | 2020-10-20 | 2021-01-15 | 贵州黔之爱生物科技有限公司 | 降血脂降血糖的刺梨食用菌茶叶发酵饮料的制备及应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105169203B (zh) | 一种砂仁提取物及其用途 | |
US10238702B2 (en) | Pharmaceutical composition, preparation method therefor and use thereof | |
CN107319553A (zh) | 一种辅助降血糖增强免疫力的保健品及其制备方法 | |
CN106063795B (zh) | 连翘苷、其衍生物、连翘苷与连翘脂素组合物在制备预防或/和治疗高血脂症药物中的应用 | |
CN108159036A (zh) | 含茶氨酸、磷脂酰丝氨酸和原花青素的缓解视疲劳的组合物 | |
CN112931883A (zh) | 一种益生元组合物及其制备方法和应用 | |
CN113768021A (zh) | 一种具有降血脂、降血糖作用的压片果糖及其制备方法 | |
CN103932000A (zh) | 一种复合双歧因子的灵芝孢子粉咀嚼片及其制备工艺 | |
CN110960502A (zh) | 一种治疗代谢综合征的物质及其应用 | |
CN104027494A (zh) | 一种具有延缓衰老及保健功效的中药组合物 | |
CN110074392A (zh) | 一种解酒保肝养胃护肠组合物及其制备方法 | |
CN110384240A (zh) | 降血糖的维生素和益生菌发酵物粉营养组合物及其应用 | |
KR20230145464A (ko) | 고지혈증을 치료하는 약물 조성물 및 그 제조 방법 | |
CN113350453B (zh) | 用于升高hdl-c的组合物 | |
CN111281902A (zh) | 木姜叶柯或其活性提取物的用途 | |
CN108653298A (zh) | 单糖组合物、药物制剂及其应用 | |
CN107897935A (zh) | 神经酸组合物及其制备方法以及保健品 | |
CN106620090A (zh) | 一种降血糖的组合物及其制备方法 | |
CN102793891B (zh) | 一种降血脂抗高尿酸的中药组合物 | |
CN110464808A (zh) | 减肥降脂中药益生元组合物及其制备方法和应用 | |
WO2019227885A1 (zh) | 一种云牛膝多糖胶囊制剂、制备方法及应用 | |
CN102846731B (zh) | 用于治疗乳腺增生或乳腺炎的中药组合物及其制备方法 | |
CN110122765A (zh) | 一种无麸质馒头及其制备方法 | |
CN107854630A (zh) | 米秕糠提取物以及制备方法和应用 | |
CN110101085A (zh) | 一种含木糖的混合糖浆型香料及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211210 |